[Pubmed] Normotensive primary aldosteronism in a patient with myasthenia gravis: a localization diagnostic conundrum unr

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6512
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Android Chrome

[Pubmed] Normotensive primary aldosteronism in a patient with myasthenia gravis: a localization diagnostic conundrum unr

Message par RSS-Bot »


Endocrine. 2025 Jun 10. doi: 10.1007/s12020-025-04311-x. Online ahead of print.

ABSTRACT

PURPOSE: While primary aldosteronism (PA) is typically screened in hypertensive patients, normotensive PA remains underrecognized, especially in complex cases where standard diagnostic approaches fail. We present a challenging case of normotensive PA complicated by myasthenia gravis (MG) requiring chronic glucocorticoids, which interfere with conventional cortisol-based adrenal venous sampling (AVS) interpretation. This case highlights the pivotal role of 68Ga-pentixafor PET/CT as an innovative alternative for subtype differentiation in such complex scenarios.

METHODS: A 30-year-old normotensive woman with MG (on long-term glucocorticoids) was incidentally found to have a left adrenal adenoma. Biochemical testing confirmed PA (elevated ARR, positive captopril challenge test and saline infusion test). Due to glucocorticoid interference with AVS interpretation, 68Ga-pentixafor PET/CT was utilized for precise localization. We further reviewed literature on alternative diagnostic strategies for PA when conventional cortisol-based AVS interpretation is compromised.

RESULTS: 68Ga-pentixafor PET/CT successfully localized the aldosterone-producing adenoma, guiding laparoscopic adrenalectomy. Postoperatively, the patient achieved complete biochemical remission (normalized ARR and potassium). To our knowledge, this is the first reported use of 68Ga-pentixafor PET/CT for PA subtype diagnosis in a glucocorticoid-dependent normotensive patient, offering a paradigm for similar challenging cases.

CONCLUSIONS: For PA patients with confounding factors affecting cortisol-based AVS interpretation (e.g., chronic glucocorticoid use), 68Ga-pentixafor PET/CT emerges as a robust non-invasive alternative for accurate subtype differentiation. This case provides a novel diagnostic framework for complex PA presentations, advocating for tailored imaging strategies to overcome traditional limitations.

PMID:40495043 | DOI:10.1007/s12020-025-04311-x


Source: https://pubmed.ncbi.nlm.nih.gov/4049504 ... t9+e462414
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »